MedTrace Logo

Fiberoptic Bronchoscopy and Bronchoalveolar Lavage in Critically Ill Ventilated Patients

NCT04502368 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2021-02-08

No results posted yet for this study

Summary

Fiberoptic bronchoscopy (FOB) is widely used as a diagnostic or therapeutic procedure in intensive care units. Patients with ARDS or COVID-19 disease often undergoes to these procedures. However, intensive care patients might suffer from serious side effects such as prolonged oxygen desaturation and adverse change in lung compliance and resistance. This study aims to evaluate these changes and determine their impact on patient stability.

Conditions

  • Fiberoptic Bronchoscopy (FOB)
  • Bronchoalveolar Lavage (BAL)
  • Respiratory Disease

Interventions

PROCEDURE

Fiberoptic Bronchoscopy (FOB)

FOB under full sedation (RASS sedation scale -5) and full paralysis.

PROCEDURE

Bronchoalveolar Lavage (BAL)

BAL under full sedation (RASS sedation scale -5) and full paralysis. Lavage: NaCl 0,9% 50ml x 3 in lung region targetted according to RX/CT scan.

DIAGNOSTIC_TEST

Electrical Impedance Tomography (EIT)

Realtime thoracic impedance coupled with ventilation parameters recording.

DIAGNOSTIC_TEST

Arterial Blood Gas test (ABG)

Multiples Arterial Blood Gas test (ABG) via arterial catheter.

Sponsors & Collaborators

  • Erasme University Hospital

    lead OTHER

Principal Investigators

  • Francesco Ricottilli, MD · Intensive Care Unit - Erasme University Hospital

  • Leda Nobile, MD · Intensive Care Unit - Erasme University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-01
Primary Completion
2021-03-30
Completion
2021-04-30

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04502368 on ClinicalTrials.gov